CN107158268A - 一种治疗高血压的中药组合物及其制备方法和应用 - Google Patents
一种治疗高血压的中药组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN107158268A CN107158268A CN201710395444.3A CN201710395444A CN107158268A CN 107158268 A CN107158268 A CN 107158268A CN 201710395444 A CN201710395444 A CN 201710395444A CN 107158268 A CN107158268 A CN 107158268A
- Authority
- CN
- China
- Prior art keywords
- parts
- hypertension
- chinese medicine
- extract solution
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 64
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 241000287828 Gallus gallus Species 0.000 claims abstract description 21
- 210000004317 gizzard Anatomy 0.000 claims abstract description 21
- 239000012528 membrane Substances 0.000 claims abstract description 21
- 235000003805 Musa ABB Group Nutrition 0.000 claims abstract description 17
- 235000014676 Phragmites communis Nutrition 0.000 claims abstract description 17
- 235000015266 Plantago major Nutrition 0.000 claims abstract description 17
- 241000405414 Rehmannia Species 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 43
- 239000000706 filtrate Substances 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 14
- 238000010992 reflux Methods 0.000 claims description 14
- 239000006210 lotion Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 241000234295 Musa Species 0.000 claims 3
- 240000008790 Musa x paradisiaca Species 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 14
- 238000000034 method Methods 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗高血压的中药组合物及其制备方法和应用。该组合物主要由如下重量份的原料药所制成:茯神28‑45份、车前子20‑40份、赤药15‑35份、玄胡5‑25份、玉竹10‑20份、山茱萸25‑35份、生地10‑25份、芦根10‑15份、黄精8‑20份、鸡内金5‑15份。本发明所得中药组合物,成本低,工艺简单,对人体无毒副作用,能够有效治疗高血压。与当前治疗高血压的化学治疗药物相比,本发明中药组合物作用全面,药物治疗效果更佳,本发明的药物组合物中由于加入了一定比例的玉竹和鸡内金与其他中药原料混合后制备的组合物可以有效地治疗患者的高血压并且复发率低、协同作用显著能够有效改善高血压的症状。
Description
技术领域
本发明涉及一种治疗高血压的中药组合物及其制备方法和应用,属于中药制剂技术领域。
背景技术
高血压(hypertension)是最常见的慢性病,也是心脑血管病最主要的危险因素,可伴有心、脑、肾等器官的功能或器质性损害的临床综合症。近年来,随着人们生活水平不断提高,饮食结构发生较大变化,我国心、脑血管疾病的发生和死亡人数也在不断上升,其中死亡人数占我国总死亡率的比例甚至已达到40%左右,高血压已经成为一个让人担忧的问题。
降压治疗的两大目的是:降低血压和减少心脑血管疾病和死亡发生,一般高血压患者,应将血压(收缩压/舒张压)降至140/90mmHg以下;65岁及以上的老年人的收缩压应控制在150mmHg以下。
目前市场上治疗高血压的中西药品种繁多。西药治疗高血压,往往能很快使血压下降,甚至恢复正常,但在改善头晕、头痛等症状上效果欠佳。而且多数西药很难控制其对靶器官的破坏。钙通道阻滞剂(CCB)是我国医生最多处方的降压药物,但其本身副作用也很明显,如反射性的引起心率增快,心搏出量增加,也反射性增加血浆肾素活性;直接扩张血管导致交感神经张力增高,引起心率增快,头痛,下肢水肿等。
而中医中药是以辨证为基础的,强调整体治疗,症状改善比较理想,能有效提高患者的生活质量;降压作用缓和,稳定血压效果好,对早期、老年轻度高血压或配合西药治疗较重的高血压病,均可防止或缓和血压较大的波动;中药副作用少,且能减轻或消除西药的副作用;目前一些研究发现,中医中药在对某些受损器官的逆转以及并发症的防治方面也有一定作用。
发明内容
发明目的:为了克服现有技术中存在的不足,本发明提供一种用于治疗高血压的中药组合物。该药物组合物能够有效地治疗高血压,并且复发率低,无副作用。
本发明还提供该种治疗高血压的中药组合物的制备方法和应用。
技术方案:为实现上述目的,本发明提供了一种治疗高血压的中药组合物,主要由如下重量份的原料药所制成:
茯神28-45份、车前子20-40份、赤药15-35份、玄胡5-25份、
玉竹10-20份、山茱萸25-35份、生地10-25份、芦根10-15份、
黄精8-20份、鸡内金5-15份。
作为优选,所述的治疗高血压的中药组合物,主要是由如下重量份的原料药所制成:
茯神35-40份、车前子25-35份、赤药20-30份、玄胡10-20份、
玉竹12-18份、山茱萸28-32份、生地15-20份、芦根12-14份、
黄精10-15份、鸡内金8-12份。
本发明所述的治疗高血压的中药组合物的制备方法,包括以下步骤:
(1)按比例称取茯神、车前子、赤药、玄胡、玉竹和山茱萸碎成粗粉,按照粗粉总重量加4-8倍水,浸泡0.5-2小时,煎煮,合并煎煮液,滤过,得到滤液A;
(2)将滤液A加入4-6倍体积的乙醇回流提取,合并提取液,回收乙醇至无醇味,得提取液B;
(3)按比例称取生地、芦根、黄精和鸡内金,加水浸泡,煮沸,过滤后向滤液加入5-6倍体积的乙醇回流提取,合并提取液,得提取液C;
(4)将提取液B和提取液C,浓缩成70℃时相对密度为1.20~1.25的膏体,即得。
其中,步骤(1)所述煎煮3-4次,每次30-40min。
步骤(2)和步骤(3)所述乙醇为体积分数60-70%的乙醇。
本发明所述的治疗高血压的中药组合物在制备治疗高血压药物中的应用。
其中,所述药物包括汤剂、口服液、片剂、胶囊剂或颗粒剂。
有益效果:相对于现有技术,本发明所得中药组合物,成本低,工艺简单,对人体无毒副作用,能够有效治疗高血压,且能够显著降低高血压复发率。与当前治疗高血压的化学治疗药物相比,本发明中药组合物作用全面,药物治疗效果更佳,本发明的药物组合物中由于加入了一定比例的玉竹和鸡内金与其他中药原料混合后制备的药物组合物可以有效地治疗患者的高血压并且复发率低、协同作用显著能够有效改善高血压的症状。
具体实施方式
下面结合实施例对本发明作更进一步的说明。
实施例1
处方:
茯神28份、车前子20份、赤药15份、玄胡5份、
玉竹10份、山茱萸25份、生地10份、芦根10份、
黄精8份、鸡内金5份。
制备工艺:
(1)按比例称取茯神、车前子、赤药、玄胡、玉竹和山茱萸碎成粗粉,按照粗粉总重量加4倍水,浸泡0.5小时,煎煮4次,每次30min,合并煎煮液,滤过,得到滤液A;
(2)将滤液A加入6倍体积的体积分数70%乙醇回流提取3次,每次1h,合并提取液,回收乙醇至无醇味,得提取液B;
(3)按比例称取生地、芦根、黄精和鸡内金,加水浸泡,煮沸,过滤后向滤液加入6倍体积的体积分数70%乙醇回流提取3次,每次1h,合并提取液,得提取液C;
(4)将提取液B和提取液C,浓缩成70℃时相对密度为1.25的膏体,即得。
膏体按照常规制剂方法制成汤剂。
实施例2
处方:
茯神45份、车前子40份、赤药35份、玄胡25份、
玉竹20份、山茱萸35份、生地25份、芦根15份、
黄精20份、鸡内金15份。
制备工艺:
(1)按比例称取茯神、车前子、赤药、玄胡、玉竹和山茱萸碎成粗粉,按照粗粉总重量加4倍水,浸泡2小时,煎煮3次,每次40min,合并煎煮液,滤过,得到滤液A;
(2)将滤液A加入4倍体积的体积分数60%乙醇回流提取2次,每次1.5h,合并提取液,回收乙醇至无醇味,得提取液B;
(3)按比例称取生地、芦根、黄精和鸡内金,加水浸泡,煮沸,过滤后向滤液加入5倍体积的体积分数60%乙醇回流提取2次,每次1.5h,合并提取液,得提取液C;
(4)将提取液B和提取液C,浓缩成70℃时相对密度为1.20的膏体,即得。
膏体按照常规制剂方法制成口服液。
实施例3
处方:
茯神35份、车前子30份、赤药25份、玄胡15份、
玉竹15份、山茱萸30份、生地18份、芦根13份、
黄精12份、鸡内金10份。
制备工艺:
(1)按比例称取茯神、车前子、赤药、玄胡、玉竹和山茱萸碎成粗粉,按照粗粉总重量加6倍水,浸泡1.5小时,煎煮3次,每次35min,合并煎煮液,滤过,得到滤液A;
(2)将滤液A加入5倍体积的体积分数70%乙醇回流提取3次,每次1h,合并提取液,回收乙醇至无醇味,得提取液B;
(3)按比例称取生地、芦根、黄精和鸡内金,加水浸泡,煮沸,过滤后向滤液加入6倍体积的体积分数70%乙醇回流提取2次,每次1h,合并提取液,得提取液C;
(4)将提取液B和提取液C,浓缩成70℃时相对密度为1.22的膏体,即得。
膏体按照常规制剂方法制成片剂。
实施例4
处方:
茯神35份、车前子25份、赤药20份、玄胡10份、
玉竹12份、山茱萸28份、生地15份、芦根12份、
黄精10份、鸡内金8份。
制备工艺:
(1)按比例称取茯神、车前子、赤药、玄胡、玉竹和山茱萸碎成粗粉,按照粗粉总重量加6倍水,浸泡1小时,煎煮4次,每次30min,合并煎煮液,滤过,得到滤液A;
(2)将滤液A加入4倍体积的体积分数60%乙醇回流提取3次,每次1.5h,合并提取液,回收乙醇至无醇味,得提取液B;
(3)按比例称取生地、芦根、黄精和鸡内金,加水浸泡,煮沸,过滤后向滤液加入6倍体积的体积分数60%乙醇回流提取2次,每次1h,合并提取液,得提取液C;
(4)将提取液B和提取液C,浓缩成70℃时相对密度为1.25的膏体,即得。
膏体按照常规制剂方法制成颗粒剂。
实施例5
处方:
茯神40份、车前子35份、赤药30份、玄胡20份、
玉竹18份、山茱萸32份、生地20份、芦根14份、
黄精15份、鸡内金12份。
制备工艺:
(1)按比例称取茯神、车前子、赤药、玄胡、玉竹和山茱萸碎成粗粉,按照粗粉总重量加8倍水,浸泡2小时,煎煮3次,每次30min,合并煎煮液,滤过,得到滤液A;
(2)将滤液A加入6倍体积的体积分数60%乙醇回流提取2次,每次2h,合并提取液,回收乙醇至无醇味,得提取液B;
(3)按比例称取生地、芦根、黄精和鸡内金,加水浸泡,煮沸,过滤后向滤液加入5倍体积的体积分数60%乙醇回流提取3次,每次1h,合并提取液,得提取液C;
(4)将提取液B和提取液C,浓缩成70℃时相对密度为1.25的膏体,即得。
膏体按照常规制剂方法制成胶囊剂。
试验例1
毒理学实验
40只SD大鼠,按体重随机分组,每组10只,将上述大鼠均口服实施例1-5制备的所得中药组合物,用量为一天用量进行急性毒性试验,给药量均为1.0g/只,结果未出现任何毒性反应,给药后观察7天,结果所有大鼠健全,其活动、饮食、毛发、排泄物未发现异常,未见毒性反应。对处死后解剖,其主要脏器观察无明显异常。
试验例2
1、一般资料
200例高血压患者,男100例,女100例。随机平均分为五组,分别为对照组1、对照组2、实施例1组、实施例2组、实施例3组,各组性别、年龄、病程等经统计学处理,差异无显著性意义(P>O.05),具有可比性。
2、治疗方法
对照组1给予缬沙坦胶囊(市售可得),按药品说明书使用,口服,一次1粒,一日1次,一个月为一个疗程。
对照组2给予与实施例3的组方和制备方法相同,不同之处在与处方中没有玉竹和鸡内金所得的中药组合物的制剂,用量为常规一天用量,一天一次,一个月为一个疗程。
实施例1组、实施例2组和实施例3组分别给予本发明实施例1、实施例2和实施例3所得中药组合物的制剂,用量为常规一天用量,一天一次,一个月为一个疗程。
3、诊断标准
根据卫生部制定的《中医新药临床研究指导原则》中高血压病疗效评定标准确定,痊愈:血压降至正常,停药一年不反弹,基本症状消失;显效:血压有明显下降,症状明显改善;无效:血压以及症状无改善。
4、治疗结果
按上述方法治疗十个疗程后,考察各组终治疗的总有效率(%),以及停药一年后的复发率(%),结果见表1。
表1各组患者临床治疗总有效率和复发率考察结果(%)
由上表1结果可见,与对照组1现有的药物相比较,本发明实施例1、2和3所得中药组合物,对于高血压的治疗效果要更好,证明其能够有效治疗高血压;同时与对照组2相比本发明的有效治愈率也更高,痊愈比例更高,说明玉竹和鸡内金在里面起到了关键性作用;而在复发率方面,本发明中药组合物治疗后的复发率最高仅为2.5%,远远低于对照组1和2,证明本发明中药组合物能够显著降低高血压的复发率,可以使患者痊愈。且在治疗过程中,且在治疗过程中,对照组1发生副反应5例,其他各治疗组均无副反应发生。
Claims (7)
1.一种治疗高血压的中药组合物,其特征在于,主要由如下重量份的原料药所制成:
茯神28-45份、车前子20-40份、赤药15-35份、玄胡5-25份、
玉竹10-20份、山茱萸25-35份、生地10-25份、芦根10-15份、
黄精8-20份、鸡内金5-15份。
2.根据权利要求1所述的治疗高血压的中药组合物,其特征在于,主要是由如下重量份的原料药所制成:
茯神35-40份、车前子25-35份、赤药20-30份、玄胡10-20份、
玉竹12-18份、山茱萸28-32份、生地15-20份、芦根12-14份、
黄精10-15份、鸡内金8-12份。
3.权利要求1-2任一项所述的治疗高血压的中药组合物的制备方法,其特征在于,包括以下步骤:
(1)按比例称取茯神、车前子、赤药、玄胡、玉竹和山茱萸碎成粗粉,按照粗粉总重量加4-8倍水,浸泡0.5-2小时,煎煮,合并煎煮液,滤过,得到滤液A;
(2)将滤液A加入4-6倍体积的乙醇回流提取,合并提取液,回收乙醇至无醇味,得提取液B;
(3)按比例称取生地、芦根、黄精和鸡内金,加水浸泡,煮沸,过滤后向滤液加入5-6倍体积的乙醇回流提取,合并提取液,得提取液C;
(4)将提取液B和提取液C,浓缩成70℃时相对密度为1.20~1.25的膏体,即得。
4.根据权利要求3所述的制备方法,其特征在于,步骤(1)所述煎煮3-4次,每次30-40min。
5.根据权利要求3所述的制备方法,其特征在于,步骤(2)和步骤(3)所述乙醇为体积分数60-70%的乙醇。
6.权利要求1-2任一项所述的治疗高血压的中药组合物在制备治疗高血压药物中的应用。
7.根据权利要求6所述的应用,其特征在于,所述药物包括汤剂、口服液、片剂、胶囊剂或颗粒剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710395444.3A CN107158268A (zh) | 2017-05-27 | 2017-05-27 | 一种治疗高血压的中药组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710395444.3A CN107158268A (zh) | 2017-05-27 | 2017-05-27 | 一种治疗高血压的中药组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107158268A true CN107158268A (zh) | 2017-09-15 |
Family
ID=59821324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710395444.3A Pending CN107158268A (zh) | 2017-05-27 | 2017-05-27 | 一种治疗高血压的中药组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107158268A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115634258A (zh) * | 2022-09-08 | 2023-01-24 | 长春中医药大学 | 一种可降血压的中药复方制剂及其制备方法 |
-
2017
- 2017-05-27 CN CN201710395444.3A patent/CN107158268A/zh active Pending
Non-Patent Citations (2)
Title |
---|
张清: "《高血脂饮食+运动+中医调养全书》", 30 April 2016, 天津科学技术出版社 * |
范虹: "《高血压防治:高血压离你有多远》", 31 May 2015, 金盾出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115634258A (zh) * | 2022-09-08 | 2023-01-24 | 长春中医药大学 | 一种可降血压的中药复方制剂及其制备方法 |
CN115634258B (zh) * | 2022-09-08 | 2023-09-19 | 长春中医药大学 | 一种可降血压的中药复方制剂及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102526276B (zh) | 一种降压药物组合物及其制备方法 | |
CN105055915A (zh) | 一种治疗高血压的中药组合物 | |
CN102488838B (zh) | 治疗病毒性心肌炎的中药组合物 | |
CN101152223B (zh) | 杨树叶酚类提取物在制备治疗心律失常的药物中的应用 | |
CN107158268A (zh) | 一种治疗高血压的中药组合物及其制备方法和应用 | |
CN102068520B (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法 | |
CN102204956B (zh) | 一种用于中风恢复期的中药组合物及其制备方法 | |
CN102727627B (zh) | 一种治疗心力衰竭的中药组合物及其制备方法和应用 | |
CN105194355A (zh) | 一种治疗原发性高血压的中药制剂 | |
CN104984097A (zh) | 一种治疗原发性高血压的中药制剂及其用途 | |
CN101732688B (zh) | 一种含有氨氯地平的药物 | |
CN101342207A (zh) | 一种治疗冠心病、心绞痛、心律失常、高血脂的中药组合物及其制备方法 | |
CN107137621A (zh) | 一种治疗高血脂的中药组合物及其制备方法和应用 | |
CN110742983B (zh) | 一种用于治疗痛风急性发作的中药制剂及其制备方法 | |
CN107137489A (zh) | 一种用于降血糖的中药组合物及其制备方法和应用 | |
CN108421020A (zh) | 一种用于治疗糖尿病视网膜病的生姜提取物及其制备方法和用途 | |
CN100367956C (zh) | 用于治疗高血压的药物 | |
CN100367959C (zh) | 一种含有依贝沙坦的药物 | |
CN101658568B (zh) | 一种中药组合物在制备治疗肺原性心脏病药物中的应用 | |
CN101152247A (zh) | 用于心脑血管疾病的药物组合物及其制备方法 | |
CN101342208A (zh) | 一种治疗冠心病、心绞痛、心律失常的中药组合物及其制备方法 | |
CN115944705A (zh) | 一种治疗慢性心力衰竭的中药组合物及其制备方法 | |
CN107233410B (zh) | 一种治疗类风湿关节炎的中药组合物 | |
CN100384466C (zh) | 调节血压的中成药及其应用 | |
CN105362703A (zh) | 一种治疗原发性高血压的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170915 |